November 8, 2005 -- Genentech said a second Phase III trial of blindness drug Lucentis showed the drug was more effective than Visudyne; AlgoRx and Corgentech reported positive data for the second Phase III trial of its fast-acting local anesthetic; Theravance signed a deal worth up to $221 million with Astellas Pharma of Japan to collaborate on a new antibiotic; Cellergy stopped a Phase III trial of an HIV protective vaginal gel because the placebo rate dropped; and Dr. Reddy’s Labs will buy the active pharmaceutical ingredients business from Roche. The Centient Biotech 200™ was up 20 points at 3867.35, a rise of .52%.
